A systematic review and meta-analysis published in the Brazilian Journal of Pharmacognosy found that cannabidiol (CBD) may reduce blood pressure in humans.
Researchers from Universidade Estadual Paulista reviewed four randomized controlled trials with a combined 104 participants. Three of the studies examined short-term CBD use, while one assessed long-term administration in hypertensive patients. The analysis showed that acute CBD intake significantly reduced systolic blood pressure, but did not have a measurable impact on diastolic pressure.
Chronic use appeared more promising, with reductions averaging 7.01 mmHg in systolic and 4.55 mmHg in diastolic blood pressure. These decreases could be clinically meaningful, especially for those with hypertension. Preclinical research has previously suggested CBD supports cardiovascular health through antioxidant, anti-inflammatory, and vasodilatory effects.
However, the review emphasized that the small number of trials, limited sample sizes, and substantial heterogeneity lowered confidence in the findings. The authors concluded that while CBD shows potential as a tool for managing blood pressure, larger and higher-quality trials are needed to determine its safety, efficacy, and clinical application.
More articles from The Marijuana Herald can be found below.
